United States: Hazy Outlook For Legislation Protecting Medical Cannabis

The fate of crucial federal legislation protecting medical cannabis producers, retailers and consumers from prosecution by the U.S. Department of Justice has recently become uncertain due to differences in House and Senate spending legislation. As Congress works to finalize the omnibus FY 2018 spending bill, a battle has emerged regarding the inclusion of the Rohrabacher-Blumenaur Amendment (formerly known as the Rohrabacher-Farr Amendment), which prohibits federal funds from being used to prevent states from implementing their own laws that authorize the use, distribution, possession or cultivation of medical cannabis.

While a pathway exists for the provision to be signed into law by the end of the year, there also exists the possibility of several developments that could result in its exclusion from the final FY 2018 omnibus spending legislation. If it is excluded, the DOJ and the agencies it administers, including the Federal Bureau of Investigations and the U.S. Drug Enforcement Administration, will be authorized, for the first time since the amendment was first enacted in 2014, to use federal funds to interfere with states where medical cannabis has been legalized.

Background — Federal Enforcement of Cannabis

To date, 29 states and the District of Columbia have legalized medical marijuana. Although two-thirds of all Americans live in such territories, cannabis remains illegal on the federal level due to its classification under the Controlled Substances Act (CSA) as a Schedule I drug, a designation awarded only to those substances considered the most dangerous.

Pursuant to the terms of the CSA, a Schedule I classification is only awarded to substances that (i) have a high potential for abuse, (ii) have no currently accepted medical use in the United States and (iii) lack accepted safety standards for use of the drug even under medical supervision. Heroin, LSD and bath salts are among the other substances classified as a Schedule I drug.

Cannabis' Schedule I classification significantly impacts the entire industry, limiting the ability of marijuana businesses to obtain banking services and intellectual property protections, among other impediments. Although there currently exists proposed legislation that would legalize cannabis on the federal level, such as the Marijuana Justice Act proposed by Sen. Cory Booker, D-N.J., previous legislative attempts to reschedule have failed, as have efforts to do so by way of litigation. See United States v Pickard, 100 F.Supp.3d 981 (2015).

Further, U.S. Attorney General Jeff Sessions has made unequivocal statements condemning cannabis, removing virtually any chance of legalization under his tenure. Sessions has maintained his position despite the fact that numerous reputable polls, such as a recent survey conducted by CBS News, reveal that over 85 percent of Americans believe medical marijuana should be legal.

The federal policy on cannabis enforcement is guided by a memorandum issued in 2013 by the then-acting Deputy Attorney General James Cole. The Cole memo states that the DOJ's position is to limit the use of federal resources by focusing its efforts on certain enforcement priorities of particular importance to the federal government.

These priorities include preventing (i) the distribution of cannabis to minors, (ii) driving while impaired due to cannabis consumption and (iii) cannabis possession or use on federal property. Attorney General Sessions has stated that the Cole Memo is under review, but to date has not adjusted or amended the policy.

The federal position on cannabis became further complicated on Sept. 26, 2017, when the acting administrator of the DEA, Chuck Rosenberg, announced his plans to step down from his position. Rosenberg strongly opposed the legalization of the cannabis industry, telling reporters in 2015 that medical marijuana "is a joke." President Donald Trump has not yet nominated a successor to Rosenberg, an Obama administration appointee, so the DEA's future position on cannabis related issues remains unclear.

Background — Rohrabacher-Farr Amendment

While the Cole memo establishes the current federal position on cannabis enforcement, it does not have the power of law and only provides guidance to U.S. attorneys. It is the aforementioned Rohrabacher-Blumenaur Amendment (hereinafter referred to as the "Amendment") that provides medical marijuana with binding legislative protection from federal intervention, stating:

None of the funds made available in this Act to the Department of Justice may be used, with respect to any [state or United States territories in which medical marijuana is legal], to prevent any of them from implementing their own laws that authorize the use, distribution, possession, or cultivation of medical marijuana.

Originally introduced by Reps. Dana Rohrabacher, R-Calif., and Sam Farr, D-Calif., and signed into law by President Barack Obama as part of a 2014 omnibus spending bill, the Amendment must be renewed each fiscal year in order to remain in effect.

Following Rep. Farr's retirement from Congress in 2017, Rep. Earl Blumenaur, D-Ore., became the lead House Democratic sponsor on the Amendment.

Current Protections in Place Through Dec. 8, 2017

In May 2017, the Rohrabacher-Blumenaur Amendment was renewed by Congress until Sept. 30, 2017, as part of a spending bill signed into law by President Donald Trump. A bipartisan short-term funding deal enacted on Sept. 8, 2017, further extended the protections through Dec. 8, 2017.

The Amendment was also upheld in the Senate where, in July 2017, the Senate Appropriations Committee approved inclusion of the Amendment in the Senate Commerce, Justice, and Science appropriations bill for fiscal year 2018. Sen. Patrick Leahy, D-Vt., the ranking Democrat on the Senate Appropriations Committee, offered the amendment.

House Rules Committee Blocks Consideration by the Full House

Earlier this month, the full House of Representatives debated and passed an omnibus FY 2018 spending bill, which is the traditional legislative vehicle for medical cannabis protections. However, in an effort to speed up the amendment process on the this massive $1 trillion spending package, House leadership required the House Rules Committee to adopt a rule that limited debate on the floor to pre-selected amendments.

The House Rules Committee chose to block the Amendment from receiving consideration by the full House. Rep. Peter Sessions (R-Tex), chairman of the House Rules Committee and vocal opponent of cannabis legislation, is attributed to be the primary advocate for blocking the Amendment from reaching a House vote.

In a statement released after the recent House Rules Committee setback, Reps. Rohrabacher and Blumenauer stated:

Committee leadership is putting at risk the millions of patients who rely on medical marijuana for treatment, as well as the clinics and businesses that support them. The American people ... overwhelmingly oppose federal interference with state marijuana laws. These critical protections are supported by a majority of our colleagues on both sides of the aisle.

With the Amendment set to expire on Dec. 8, 2017, the future of its protections now hinges on the work of the House-Senate conference committee, which will reconcile the differences between the spending bills of the two chambers this fall.

In their recent statement, Reps. Rohrabacher and Blumenauer advocated for protecting medical cannabis policies enacted by each individual state. The representatives said, "as House and Senate leadership negotiate a long-term funding bill, we will fight to maintain current protections."

Democratic Votes May Be Needed for Spending Bill, and Cannabis Protections Could Be a Sweetener

Legislation to extend funding for federal government operations and the funding provisions associated with these operations, such as the Amendment, is debated and approved though the annual appropriations process. Although Republicans hold majorities in both the House and the Senate, fiscally conservative Republicans often oppose appropriations bills authored by members of their own party.

For example, the most recent extension of federal funding, which also included a debt limit increase, was opposed by 17 Republicans in the Senate and 90 Republicans in the House. With this many defectors, the continuing of federal funding until December was only possible with Democratic support.

It is expected that the House and Senate will approve the final FY 2018 omnibus spending legislation and a longer-term debt limit increase in December, and once again, it is anticipated that Democrats will be needed in order to get a bill to the president's desk for signature to avoid a government shutdown.

While the Amendment has the support of many Republicans, including its backer Rep. Rohrabacher, it is more heavily favored by Democrats. As House and Senate leadership negotiate the final spending package, the inclusion of medical marijuana protections could be one of many incentives for Democrats to support the bill.

Lobbying and Other Actions in the Coming Weeks Will Impact the Outcome

Reps. Rohrabacher and Blumenaur are in the process of collecting signatures of their fellow congressmen for a letter to leadership of House and Senate Appropriations Committees urging them to keep the medical marijuana language offered by Sen. Leahy in the final package.

Advocates for the cannabis industry are actively lobbying Congress in order to secure as many signers of the letter as possible. If enough members of Congress sign the letter, it will give negotiators good cause to keep the provision in the final package.

However, several events could occur that could lead negotiators to omit the provision. First, if the House support letter fails to get a critical mass of signatures, it could be perceived by appropriations negotiators as a sign of waning support for the protections contained in the Amendment.

Second, Attorney General Jeff Sessions could choose to make a policy statement in opposition to the provision. While it is widely known that Attorney General Sessions opposes legal access to marijuana, he has yet to take steps to enforce his position. While cabinet members and other officials don't have a direct vote on legislation, they can insert themselves into the negotiation process if the White House backs their efforts.

The relationship between President Trump and Attorney General Sessions has been strained at times, but if the White House wanted to show unity, it could choose to support an initiative raised by the Attorney General. Since the president must approve or disapprove any bill passed, House and Senate appropriators will take their positions seriously.

Lastly, the Amendment could face trouble if opponents of medical marijuana increase their lobbying. In the past, various law enforcement groups, the Family Research Council and other organizations have made fighting medical marijuana legalization a priority.

There is not currently any indication that this is an active issue for these groups, but there is nothing to stop them from making this a issue again soon. These opponents can make a case against the Amendment that is appealing to some lawmakers, and their influence should not be underestimated.

Significance and Industry Expectations

While its protections do not extend to the recreational cannabis industry or to those engaging in medical marijuana activity in violation of applicable state law, the Amendment has served as the primary security blanket for the medical marijuana industry over the past three years. Unless cannabis is legalized on the federal level, an unlikely scenario under the current administration, its absence will deprive state-compliant medical marijuana operators and users of their one substantive protection against federal intervention.

Thus, even in an industry that is well-accustomed to regulatory uncertainty, the fate of this particular legislation is of monumental importance for medical marijuana operators and patients. During this critical time, advocates and interested parties are strongly encouraged to engage their congressional representatives either directly or through a lobbyist.

While nothing is certain, the consensus among most Capitol Hill insiders appears to be that the Amendment will ultimately be included in the final omnibus FY 2018 spending bill. This prediction is primarily due to the ongoing public support for medical marijuana, the onslaught of states that have legalized medical marijuana in recent years and the potential for the Amendment to be used as a bargaining chip to garner Democratic support for the spending package.

Nevertheless, enough uncertainty exists to put the medical marijuana community on edge as the Amendment's expiration date of Dec. 8, 2017, draws closer.

This article was originally published in the Expert Analysis section of Law360.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions